This study looks at how safe and effective KarXT + KarX-EC is for helping people with cognitive impairment (trouble thinking and remembering) due to Alzheimer's Disease (AD). AD is a brain condition that affects memory and thinking. Participants must have mild or moderate AD and a caregiver to assist them. They should also be on stable doses of certain medications, like acetyl choline esterase inhibitors and memantine, for at least 12 weeks before joining and throughout the study. People with serious health issues or psychiatric disorders cannot join. Also, participants should not have had other treatments interfering with AD or significant brain problems on an MRI. The study will assess whether the treatment helps with thinking and memory and if it is safe for participants.

• The study requires participants to have a caregiver who can help and attend all visits.
• Participants must have stable medication doses before and during the study.
• People with significant health problems or psychiatric disorders cannot join.